April 4, 2022


This study observed the effects on tumor growth, propagation, and lifespan when medicated with different doses, combinations, and ratios of combinations of CBN, CBD, and Delta-9 & Delta-8 THC in mice. Some major observations included slower tumor growth in subjects dosed with Delta-9 THC, smaller tumor size observed in subjects dosed with CBN and Detla-8 THC, and a combination CBN, Delta-8, and Delta-9 was observed to increase mean lifespan of the tumor implanted mice by 36% over control.
November 8, 2021

THC 2.5mg

THC and placebo groups were comparable at baseline. Compared with placebo, THC-treated patients reported improved and enhanced chemosensory perception and food 'tasted better'. Premeal appetite and proportion of calories consumed as protein increased compared with placebo. THC-treated patients reported increased quality of sleep and relaxation. Quality of life scores and total caloric intake increased lead to the conclusion that THC may be useful in the palliation of chemosensory alterations and to improve food enjoyment for cancer patients.
November 8, 2021

THC:CBD Being conducted 1:1 2.5:2.5 / 10:10 / 30:30

Despite improvements in medical care, patients with advanced cancer still experience substantial symptom distress. There is increasing interest in the use of medicinal cannabinoids but little high-quality evidence to guide clinicians. This study aims to define the role of a 1:1 delta-9-tetrahydrocannabinol/cannabidiol (THC/CBD) cannabinoid preparation in the management of symptom burden in patients with advanced cancer undergoing standard palliative care.
October 22, 2021

THC vs Alternatives 2.5mg

Taste and smell disturbances in patients affected by cancer are very common, but often under-recognized symptoms. If not addressed properly, they may impact nutritional status, food enjoyment, and quality of life. Treatment tools available for clinicians to manage chemosensory alterations are limited and are often based on personal clinical experiences. The aim of this study was to assess current oncological and palliative care literature through a scoping review, in order to identify available treatments for taste and smell alterations in cancer patients. This review examines. A broad variety of treatment options were described including zinc and polaprezinc, radio-protectors, vitamins and supplements, anti-xerostomia agents, active swallowing exercises, nutritional interventions, delta-9-tetrahydrocannabinol, and photobiomodulation.
    Your Cart
    Your cart is emptyReturn to Shop